Van ECK Associates Corp reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.5% in the 3rd quarter, according to the company in its most recent 13F filing with the ...

Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...

According to Benzinga Pro, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 10.61%, which means the company has more short interest than most of its peers. Did ...

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.

Halozyme Therapeutics ( (HALO) ) has released its Q3 earnings. Here is a breakdown of the information Halozyme Therapeutics presented to its ...

On Thursday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $50.57 which represents a decrease of $-0.02 or -0.04% from the prior close of $50.59. The stock opened at $50.56 ...

Halozyme Therapeutics, Inc. HALO reported third-quarter 2024 adjusted earnings of $1.27 per share, which comprehensively beat ...

As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...